Posts

When the Perfect Exit Creates Integration Risk: KCar, Hologic, and the Illusion of the Clean Handover

Two deals closed in April 2026 that, on paper, look like textbook private equity success stories. On April 1, KG Group agreed to acquire K Car — South Korea's largest used-car platform — from Han & Company for ₩550 billion ($390M+). The total exit proceeds, including the affiliated financing subsidiary KCar Capital, reached ₩750 billion. Enterprise value was assessed at roughly ₩1 trillion. A clean exit, years in the making. Six days later, on April 7, Blackstone and TPG completed their $17.2 billion take-private of Hologic, a U.S.-listed women's health and diagnostics company. Shareholders received $76 per share in cash, with a contingent payment of up to $3 more tied to revenue performance in the Breast Health division. Abu Dhabi Investment Authority and Singapore's GIC joined as minority investors. On closing day, the CEO of 12 years stepped down. A new executive, Joe Almeida, took the chair. Two continents. Two asset classes. One shared challenge: the integrat...
Post a Comment
Read more

The Day After the Deal: What McCormick vs. Unilever Teaches Us About PMI at Scale

When McCormick announced on March 31, 2026 that it would acquire Unilever’s food business for approximately $44.8 billion, the headlines focused on the numbers — $15.7 billion in cash, Hellmann’s and Marmite and Knorr folded into a spice and condiment giant. Shares of both companies fell on the day: McCormick by 6%, Unilever by 4%. But behind the stock market reaction lies a more fundamental question for integration practitioners: how do you absorb a century-old portfolio of European consumer brands into a Maryland-headquartered flavor company without breaking what made them valuable? The PMI Challenge at Scale Haspeslagh and Jemison (1991), in their foundational study of post-merger integration, observed that the primary failure mode in large acquisitions was not financial incompatibility — it was what they termed “capability transfer failure”: the inability to move the organizational routines, relationships, and tacit knowledge that underpin competitive advantage across the com...
Post a Comment
Read more

PE Take-Privates in Asia: Why Seoul and Tokyo Are Delisting in 2026

Two deals announced in the same week of April 2026 tell a story that goes beyond individual transactions. In Seoul, private equity firm Hahn & Company completed its exit from KCar — Korea's largest direct used-car platform — selling a 72.19% stake to industrial conglomerate KG Group for ₩550 billion, with Cactus PE acquiring the affiliated financing arm KCar Capital for an additional ₩200 billion. The total exit package reached ₩750 billion (approximately $545 million). Hahn had originally acquired the business in 2018 from SK Encar's direct sales division for roughly ₩220 billion. In Tokyo, KKR & Co. announced a ¥528.56 billion ($3.3 billion) tender offer for Taiyo Holdings, the world's leading producer of solder resist ink used in printed circuit boards. The offer price of ¥4,750 per share represented a 117% premium to the six-month volume-weighted average. Taiyo's board of directors unanimously supported the bid. Its largest shareholder, DIC Corporation, th...
Post a Comment
Read more

The Accountability Imperative: How Activist Shareholders and PE Buyouts Are Rewriting Corporate Governance in 2026

Post a Comment
Read more

When Traditional Finance Buys Crypto: The PMI Risks Nobody Prices

Today, Mirae Asset Consulting formally disclosed its acquisition of a 92.06% stake in Korbit — South Korea's fourth-largest cryptocurrency exchange — for approximately ₩133.5 billion ($96 million). The announcement came the same morning Goldman Sachs reported Q1 2026 earnings amid a record-breaking global M&A quarter: $1.2 trillion in deals, up 42% from Q1 2025 (FinancialContent/MarketMinute, April 9, 2026). The juxtaposition is instructive. Wall Street's "fee machine" is roaring back to life. In Korea, a traditional financial conglomerate has crossed a sector boundary most would have called impassable eighteen months ago. These are not separate stories — they are the same story told in two currencies. The Structural Arbitrage Mirae Asset's acquisition structure is notable for what it reveals. The buyer of record is not a bank, an insurance company, or a securities firm — it is Mirae Asset Consulting, a non-financial affiliate. This design was deliberate...
Post a Comment
Read more

When Winning Isn't Enough: Edinburgh Worldwide, Bain Capital Korea, and the Structural Logic of Relational Risk

■ The Edinburgh Paradox Edinburgh Worldwide Investment Trust (EWI), managed by Baillie Gifford, has defeated Saba Capital Management at the ballot box twice. In January 2026, 53.2% of shareholders voted to retain the incumbent board, and over 90% of non-Saba shareholders rejected Saba's nominees. Yet in April 2026, EWI's board is proposing a 100% exit tender offer — effectively winding down a 28-year-old institution. The board has warned there is a "high probability" that Saba wins control at the April 30 AGM. How does a twice-defeated activist maintain the ability to threaten corporate dissolution? The answer is structural, not transactional. ■ Relational Architecture, Not Vote Counts Saba Capital holds 31% of EWI's shares. That is not a financial position — it is a persistent structural presence in the governance network. No individual vote can neutralize the permanent relational authority of a 31% block. Every resolution, every strategy, every board appointment...
Post a Comment
Read more

CVC's Recordati $12.7 billion Mega LBO

  Review of Private Equity, Pharmaceutical, Infrastructure Privatization, and Relationship Risks CVC's Recordati $12.7 billion Mega LBO Relational Risk Research Institute | Research Session | 2026-04-10 Participating Researchers: Warren (Economist) Sam (AI Specialist) Phill (Social Philosopher) Key figures $12.7bn CVC's acquisition of Recordati deal size Equity $6.4–7.0bn + Debt $5.7–6.3bn 6.7 times Debt / EBITDA Leverage Ratio Exceeding the safety zone standard of 4.5 times +34% Average drug price increase rate within 3 years after PE acquisition R&D investment decreased by an average of 18% during the same period. Deal Structure Overview item Number / Content Transaction volume $12.7bn (approximately 17.2 trillion won) Equity injection $6.4–7.0 billion (leverage ratio approx. 45–50%) debt financing $5.7~6.3bn EV / EBITDA multiple Approximately 14 times (based on EBITDA €900M) Debt / EBITDA 6.7x — Moody's Pharmaceuticals LBO exceeds safety zone (4.5x) Joint investor co...
Post a Comment
Read more